Pharmaceutical Executive Daily: New Research on Ozempic
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
The FDA has approved Bayer’s Lynkuet, also known as elinzanetant, for the treatment of moderate to severe vasomotor symptoms associated with menopause.
New research suggests Ozempic may reduce biological age.
Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.
Lynkuet provides a non-hormonal option for patients seeking relief from menopausal symptoms without estrogen exposure, based on Phase III OASIS trial data.
The approval is based on significant reductions in hot flash frequency and severity.
Author's summary: New research on Ozempic and FDA approval.